Summary

Changes in National Insurance Reimbursement with Introduction of the DPC Package Payment System for 131I Therapy for Hyperthyroidism

Sadahiro WATANABE,* Shigeru KOSUDA,* Fuzuki YANO,* Katsumi ABE,* Shoichi KUSANO* and Yuji TANAKA**

*Department of Radiology, National Defense Medical College
**Third Department of Internal Medicine, National Defense Medical College

The inpatient DPC package payment system lowers national insurance reimbursement as compared to the former fee-for-service payment system for inpatients, when an inpatient with hyperthyroidism or toxic multinodular goiter (TMNG) is admitted for 2-day radioiodine therapy. The differentials are ¥29,970 and ¥48,870 for a 2-day hospital stay for administration of 555 MBq and 925 MBq, respectively. We request the Health and Labor Ministry to newly establish the fee for 131I internal therapy for hyperthyroidism. Furthermore, the fee should be paid according to the fee-for-service payment system.

Key words: Radioiodine therapy, Hyperthyroidism, Toxic multinodular goiter.